These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

330 related articles for article (PubMed ID: 9762351)

  • 21. Pemetrexed: a multitargeted antifolate agent with promising activity in solid tumors.
    Adjei AA
    Ann Oncol; 2000 Oct; 11(10):1335-41. PubMed ID: 11106124
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Prevention of thymidine and hypoxanthine rescue from MTA (LY231514) growth inhibition by dipyridamole in human lung cancer cell lines.
    Smith PG; Marshman E; Calvert AH; Newell DR; Curtin NJ
    Semin Oncol; 1999 Apr; 26(2 Suppl 6):63-7. PubMed ID: 10598557
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Deaza analogs of folic acid as antitumor agents.
    Kisliuk RL
    Curr Pharm Des; 2003; 9(31):2615-25. PubMed ID: 14529545
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Anticancer antifolates: current status and future directions.
    McGuire JJ
    Curr Pharm Des; 2003; 9(31):2593-613. PubMed ID: 14529544
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Mechanisms of resistance to N-[5-[N-(3,4-dihydro-2-methyl-4- oxoquinazolin-6-ylmethyl)-N-methylamino]-2-thenoyl]-L-glutamic acid (ZD1694), a folate-based thymidylate synthase inhibitor, in the HCT-8 human ileocecal adenocarcinoma cell line.
    Lu K; Yin MB; McGuire JJ; Bonmassar E; Rustum YM
    Biochem Pharmacol; 1995 Jul; 50(3):391-8. PubMed ID: 7646540
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Pemetrexed disodium (Eli Lilly).
    Norman P
    Curr Opin Investig Drugs; 2001 Nov; 2(11):1611-22. PubMed ID: 11763166
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Loss of folylpoly-gamma-glutamate synthetase activity is a dominant mechanism of resistance to polyglutamylation-dependent novel antifolates in multiple human leukemia sublines.
    Liani E; Rothem L; Bunni MA; Smith CA; Jansen G; Assaraf YG
    Int J Cancer; 2003 Feb; 103(5):587-99. PubMed ID: 12494465
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Multifactorial resistance to 5,10-dideazatetrahydrofolic acid in cell lines derived from human lymphoblastic leukemia CCRF-CEM.
    Pizzorno G; Moroson BA; Cashmore AR; Russello O; Mayer JR; Galivan J; Bunni MA; Priest DG; Beardsley GP
    Cancer Res; 1995 Feb; 55(3):566-73. PubMed ID: 7834626
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Biochemical pharmacology of pemetrexed.
    Calvert AH
    Oncology (Williston Park); 2004 Nov; 18(13 Suppl 8):13-7. PubMed ID: 15655931
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The mechanism of transport of the multitargeted antifolate (MTA) and its cross-resistance pattern in cells with markedly impaired transport of methotrexate.
    Zhao R; Babani S; Gao F; Liu L; Goldman ID
    Clin Cancer Res; 2000 Sep; 6(9):3687-95. PubMed ID: 10999762
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The synthesis and biological activity of a series of 2,4-diaminopyrido[2,3-d]pyrimidine based antifolates as antineoplastic and antiarthritic agents.
    Gossett LS; Habeck LL; Shackelford KA; Mendelsohn LG; Gates SB; Worzalla JF; Self TD; Theobald KS; Andis SL; Schultz RM; Shih C
    Bioorg Med Chem Lett; 1999 Jan; 9(1):75-8. PubMed ID: 9990460
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Overview of phase I trials of multitargeted antifolate (MTA, LY231514).
    Rinaldi DA
    Semin Oncol; 1999 Apr; 26(2 Suppl 6):82-8. PubMed ID: 10598560
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Folate status and the safety profile of antifolates.
    Calvert H
    Semin Oncol; 2002 Apr; 29(2 Suppl 5):3-7. PubMed ID: 12023786
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Thymidylate synthase level as the main predictive parameter for sensitivity to 5-fluorouracil, but not for folate-based thymidylate synthase inhibitors, in 13 nonselected colon cancer cell lines.
    van Triest B; Pinedo HM; van Hensbergen Y; Smid K; Telleman F; Schoenmakers PS; van der Wilt CL; van Laar JA; Noordhuis P; Jansen G; Peters GJ
    Clin Cancer Res; 1999 Mar; 5(3):643-54. PubMed ID: 10100718
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Loss of reduced folate carrier function and folate depletion result in enhanced pemetrexed inhibition of purine synthesis.
    Zhao R; Zhang S; Hanscom M; Chattopadhyay S; Goldman ID
    Clin Cancer Res; 2005 Feb; 11(3):1294-301. PubMed ID: 15709201
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Differences in the induction of DNA damage, cell cycle arrest, and cell death by 5-fluorouracil and antifolates.
    Backus HH; Pinedo HM; Wouters D; Kuiper CM; Jansen G; van Groeningen CJ; Peters GJ
    Oncol Res; 2000; 12(5):231-9. PubMed ID: 11417748
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Sequence-dependent administration of raloxifene and 5-fluorouracil/pemetrexed protects against pemetrexed cytotoxicity in human bone marrow.
    Das JR; Fryar-Tita EB; Green S; Southerland WM; Bowen D
    Anticancer Res; 2007; 27(2):825-33. PubMed ID: 17465208
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Role of folic acid in modulating the toxicity and efficacy of the multitargeted antifolate, LY231514.
    Worzalla JF; Shih C; Schultz RM
    Anticancer Res; 1998; 18(5A):3235-9. PubMed ID: 9858888
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Interaction of pemetrexed disodium (ALIMTA, multitargeted antifolate) and irradiation in vitro.
    Bischof M; Weber KJ; Blatter J; Wannenmacher M; Latz D
    Int J Radiat Oncol Biol Phys; 2002 Apr; 52(5):1381-8. PubMed ID: 11955753
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Computer modelling of antifolate inhibition of folate metabolism using hybrid functional petri nets.
    Assaraf YG; Ifergan I; Kadry WN; Pinter RY
    J Theor Biol; 2006 Jun; 240(4):637-47. PubMed ID: 16352313
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.